The Handbook of Clinical Neurology volumes on Traumatic Brain Injury (TBI) provide the reader with an updated review of emerging approaches to TBI research, clinical management and patient rehabilitation. Chapters in Part II offer coverage of clinical sequelae and long-term outcome, brain plasticity and long-term risks, and clinical trials. Contemporary investigations on blast injury and chronic traumatic encephalopathy are presented, making this state-of-the-art volume a must have for clinicians and researchers concerned with the clinical management, or investigation, of TBI.
- Internationally renowned scientists describe cutting edge research on the neurobiological response to traumatic brain injury, including complications to movement, mood, cognition and more
- Explores cellular/molecular and genetic factors contributing to plasticity
- Presents up-to-date expert recommendation for clinical trials and issues related to effective rehabilitation
- New findings are included on the long-term effects of traumatic brain injury that may impact aging and lead to dementia
Section 6 Clinical Sequelae and Long-Term Outcome 29. Predicting Outcome after Traumatic Brain Injury 30. Movement disorders secondary to craniocerebral trauma 31. Language impairments in traumatic brain injury: a window into complex cognitive performance 32. Connecting clinical and experimental investigations of awareness in traumatic brain injury 33. Post-Traumatic Epilepsy 34. Autonomic Dysfunction Syndromes after Acute Brain Injury 35. Sleep in traumatic brain injury 36. Post traumatic headaches 37. Traumatic brain injury and cognition 38. Mood disorders 39. Post-traumatic stress disorder and traumatic brain injury 40. Long term functional outcomes and psychosocial consequences of traumatic brain injury 41. Sequelae in Children: Developmental Consequences
Section 7 Brain Plasticity and Long-Term Risks 42. Cellular and Molecular Neuronal Plasticity 43. Traumatic brain injury and reserve 44. Traumatic brain injury and late-life dementia 45. Genetic factors in traumatic brain injury
Section 8 Conducting Clinical Trials in Traumatic Brain Injury 46. Ethical and Regulatory Considerations in the Design of Traumatic Brain Injury Clinical Studies 47. Design of Acute Neuroprotection Studies 48. Design of brain injury rehabilitation treatment research 49. The ebb and flow of traumatic brain injury research
Jordan Grafman, PhD, is director of Brain Injury Research at the Rehabilitation Institute of Chicago. Before joining RIC, Dr. Grafman was director of the Traumatic Brain Injury Research at Kessler Foundation. His investigation of brain function and behavior contributes to advances in medicine, rehabilitation, and psychology, and informs ethics, law, philosophy, and health policy. His study of the human prefrontal cortex and cognitive neuroplasticity incorporates neuroimaging and genetics, an approach that is expanding our knowledge of the impact of traumatic brain injury, as well as other diseases that impair brain function, such as stroke, multiple sclerosis and degenerative diseases. Dr. Grafman aims to translate his research into more effective, targeted rehabilitation to achieve the best outcomes for people with cognitive disabilities. Dr. Grafman's background includes 30 years of experience in brain injury research. He has studied brain function in dementia, depression, and degenerative neurological diseases, as well as TBI. He has authored more than 300 research publications, co-editor of the journal Cortex, and provides peer review for numerous specialty journals. At the National Institutes of Health, he served as chief of the Cognitive Neuroscience Section at the National Institute of Neurological Disorders and Stroke. While in the US Air Force, he served at Walter Reed Army Medical Center as neuropsychology chief of the Vietnam Head Injury Project, a long-term study of more than 500 soldiers with serious injuries of the head and brain. He is the leading expert on the long-term effects of penetrating brain injuries in military personnel. His expertise includes the scope of challenges faced during recovery, including behavioral changes like aggression, late sequelae such as seizures, and the impact on TBI on family life and employment, and legal implications. He is an elected fellow of the American Psychological Association and the New York Academy of Sciences. Dr. Grafman is the recipient of many prestigious awards including the Department of Defense Meritorious Service Award, the National Institutes of Health Award of Merit, 2010 National Institutes of Health Director's Award, and the Humboldt Reserach Award. He is a frequent speaker at national and international conferences. His expert opinion is often sought by national media on issues related to brain function and behavior, cognitive rehabilitation, and policy and legal issues related to brain-behavior research.
Salazar, Andres M.
Andres M. Salazar, MD, is CEO, Scientific Director and cofounder of Oncovir, Inc., a pharmaceutical company developing the immunomodulator, Hiltonol® (Poly-ICLC). He is a retired US Army Colonel and formerly Professor of Neurology at USUHS. He was Director of the Vietnam Head Injury Study and Founder, Principal Investigator, and first Director of the Defense and Veterans Head Injury Program, an ongoing U.S. National Head Injury clinical management and research effort. His research background includes neurotraumatology, neurodegenerative diseases, multiple sclerosis (MS), AIDS, and Oncology. He has over 200 publications, several patents, and has conducted multiple clinical studies, including in head injury, AIDS, pilot and pivotal clinical trials of beta-interferon (Avonex) in multiple sclerosis, and clinical trials of Hiltonol® in various cancers, MS, and AIDS. Dr. Salazar is a graduate of Dartmouth College and Jefferson Medical College. He completed Neurology training at Walter Reed Army Medical Center, and a Neurovirology Fellowship at the CNSSL, National Institutes of Health, Bethesda, MD.